Cancer Targeted Gene Panel Gastrointestinal Stromal Tumor (GIST) Test
Price: 4680.0 AED
Test Name: CANCER TARGETED GENE PANEL GASTROINTESTINAL STROMAL TUMOR (GIST) Test
Components: CD117, DOG-1, ERBB2, KIT, BRAF, PDGFRA, TP53
Sample Condition: Submit Formalin fixed paraffin embedded tissue block. Ship at room temperature. Duly filled NGS Test Requisition Form is mandatory.
Report Delivery: Sample due by Tuesday 9 am; Report within 10 working days
Method: Immunohistochemistry, NGS
Test Type: Cancer
Doctor: Oncologist
Test Department: Molecular Diagnostics
Pre Test Information: Duly filled NGS Test Requisition Form is mandatory.
Test Details
The Cancer Targeted Gene Panel for Gastrointestinal Stromal Tumor (GIST) is a diagnostic test that analyzes specific genes associated with GIST to aid in the diagnosis, prognosis, and treatment decisions for patients with this type of cancer.
GIST is a rare type of tumor that originates in the gastrointestinal tract, typically in the stomach or small intestine. The most common genetic abnormality found in GIST is a mutation in the KIT gene, which leads to the overgrowth of certain cells and the development of tumors.
The Cancer Targeted Gene Panel for GIST examines multiple genes, including KIT, PDGFRA, and others, to identify specific mutations or alterations that may be driving the growth of the tumor. This information can help determine the appropriate treatment options for the patient, as certain mutations may respond better to targeted therapies or other medications.
The test is usually performed on a tumor sample obtained through a biopsy or surgical resection. The sample is analyzed using advanced molecular techniques, such as next-generation sequencing, to detect mutations or other genetic alterations in the tumor cells.
The results of the test can provide valuable information about the prognosis of the patient, as certain mutations may be associated with more aggressive disease or resistance to certain treatments. It can also guide treatment decisions, as targeted therapies specifically designed to inhibit the activity of mutated genes may be more effective than traditional chemotherapy or surgery alone.
Overall, the Cancer Targeted Gene Panel for GIST is a valuable tool in the management of patients with this type of cancer, providing important information for personalized treatment approaches and improving patient outcomes.
| Test Name | CANCER TARGETED GENE PANEL GASTROINTESTINAL STROMAL TUMOR GIST Test |
|---|---|
| Components | *CD117*DOG-1*ERBB2*KIT*BRAF *PDGFRA*TP53 |
| Price | 4680.0 AED |
| Sample Condition | SubmitFormalin fixed paraffin embedded tissue block. Ship at room temperature. Duly filled NGS Test Requisition Formis mandatory. |
| Report Delivery | SampleTue by 9 am; Report 10 Working days |
| Method | Immunohistochemistry, NGS |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | MOLECULAR DIAGNOSTICS |
| Pre Test Information | Duly filled NGS Test Requisition Formis mandatory. |
| Test Details | The Cancer Targeted Gene Panel for Gastrointestinal Stromal Tumor (GIST) is a diagnostic test that analyzes specific genes associated with GIST to aid in the diagnosis, prognosis, and treatment decisions for patients with this type of cancer. GIST is a rare type of tumor that originates in the gastrointestinal tract, typically in the stomach or small intestine. The most common genetic abnormality found in GIST is a mutation in the KIT gene, which leads to the overgrowth of certain cells and the development of tumors. The Cancer Targeted Gene Panel for GIST examines multiple genes, including KIT, PDGFRA, and others, to identify specific mutations or alterations that may be driving the growth of the tumor. This information can help determine the appropriate treatment options for the patient, as certain mutations may respond better to targeted therapies or other medications. The test is usually performed on a tumor sample obtained through a biopsy or surgical resection. The sample is analyzed using advanced molecular techniques, such as next-generation sequencing, to detect mutations or other genetic alterations in the tumor cells. The results of the test can provide valuable information about the prognosis of the patient, as certain mutations may be associated with more aggressive disease or resistance to certain treatments. It can also guide treatment decisions, as targeted therapies specifically designed to inhibit the activity of mutated genes may be more effective than traditional chemotherapy or surgery alone. Overall, the Cancer Targeted Gene Panel for GIST is a valuable tool in the management of patients with this type of cancer, providing important information for personalized treatment approaches and improving patient outcomes. |
